LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 102

Search options

  1. Book: Fetal and neonatal brain injury

    Stevenson, David K. / Benitz, William E. / Sunshine, Philip / Hintz, Susan R. / Druzin, Maurice L.

    (Cambridge medicine)

    2018  

    Author's details edited by David K. Stevenson, William E. Benitz, Philip Sunshine, Susan R. Hintz, Maurice L. Druzin
    Series title Cambridge medicine
    Keywords Brain Injuries ; Infant, Newborn ; Brain Diseases ; Fetal Diseases ; Pregnancy Complications ; Birth Injuries
    Language English
    Size xiii, 831 Seiten, Illustrationen, Diagramme
    Edition Fifth edition
    Publisher Cambridge University Press
    Publishing place Cambridge
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT019724331
    ISBN 978-1-107-11080-9 ; 978-1-316-27549-8 ; 9781108515061 ; 1-107-11080-7 ; 1-316-27549-3 ; 1108515061
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Book: A critique of fetal surveillance tests

    Druzin, Maurice L.

    (Clinical obstetrics and gynecology ; 45,4)

    2002  

    Title variant Lifestyle issues in women
    Author's details Maurice L. Druzin, guest ed
    Series title Clinical obstetrics and gynecology ; 45,4
    Collection
    Language English
    Size IX S., S. 973 - 1251 : graph. Darst.
    Publisher Lippincott Williams & Wilkins
    Publishing place Hagerstown, Md
    Publishing country United States
    Document type Book
    HBZ-ID HT013562063
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  3. Book: Antepartum fetal assessment

    Druzin, Maurice L.

    1992  

    Author's details ed. by Maurice L. Druzin
    Keywords Fetal Diseases / diagnosis ; Fetal Monitoring / methods ; Prenatal Diagnosis / methods
    Size XVI, 219 S. : Ill., graph. Darst.
    Edition 1. [Dr.]
    Publisher Blackwell
    Publishing place Boston u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT004445613
    ISBN 0-86542-139-0 ; 978-0-86542-139-4
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  4. Article: Intrahepatic Cholestasis of Pregnancy and Transaminitis in Women with COVID-19: A Case Series.

    Waldrop, Anne R / Henkel, Andrea / Lee, Kelley B / Druzin, Maurice L / Aziz, Natali / El-Sayed, Yasser / Lyell, Deirdre J

    AJP reports

    2024  Volume 14, Issue 1, Page(s) e16–e18

    Abstract: ... ...

    Abstract Objective
    Language English
    Publishing date 2024-01-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2628074-7
    ISSN 2157-7005 ; 2157-6998
    ISSN (online) 2157-7005
    ISSN 2157-6998
    DOI 10.1055/s-0043-1777999
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Systemic lupus erythematosus in pregnancy: high risk, high reward.

    Do, Samantha C / Druzin, Maurice L

    Current opinion in obstetrics & gynecology

    2019  Volume 31, Issue 2, Page(s) 120–126

    Abstract: Purpose of review: The aim of this study was to describe risks of systemic lupus erythematosus (SLE) in pregnancy and the importance of preconception counselling, medication optimization and close surveillance.: Recent findings: Advances in care for ... ...

    Abstract Purpose of review: The aim of this study was to describe risks of systemic lupus erythematosus (SLE) in pregnancy and the importance of preconception counselling, medication optimization and close surveillance.
    Recent findings: Advances in care for pregnant patients with SLE have led to improved obstetric outcomes, but maternal and foetal risks continue to be elevated. Conception during periods of disease quiescence and continuation of most medications decrease adverse pregnancy outcomes. Hydroxychloroquine (HCQ) appears protective against flares in pregnancy, neonatal congenital heart block and preterm birth.
    Summary: SLE in pregnancy confers increased maternal and foetal risks, including disease flares, preeclampsia, preterm birth, foetal growth restriction, neonatal lupus erythematosus (NLE) and congenital heart block. Disease control on an effective medication regimen mitigates many of these risks, but pregnancy in women with SLE remains a high-risk condition requiring multidisciplinary care and an individualized approach to each patient.
    MeSH term(s) Adult ; Counseling ; Female ; Fetal Growth Retardation/chemically induced ; Humans ; Hydroxychloroquine/adverse effects ; Hydroxychloroquine/therapeutic use ; Lupus Erythematosus, Systemic/physiopathology ; Lupus Erythematosus, Systemic/therapy ; Practice Guidelines as Topic ; Preconception Care/methods ; Pregnancy ; Pregnancy Complications/chemically induced ; Pregnancy Complications/physiopathology ; Premature Birth/chemically induced
    Chemical Substances Hydroxychloroquine (4QWG6N8QKH)
    Language English
    Publishing date 2019-01-24
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1049382-7
    ISSN 1473-656X ; 1040-872X
    ISSN (online) 1473-656X
    ISSN 1040-872X
    DOI 10.1097/GCO.0000000000000528
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Hydroxychloroquine in Lupus Pregnancy and Risk of Preeclampsia.

    Rector, Amadeia / Marić, Ivana / Chaichian, Yashaar / Chakravarty, Eliza / Cantu, Miranda / Weisman, Michael H / Shaw, Gary M / Druzin, Maurice L / Simard, Julia F

    Arthritis & rheumatology (Hoboken, N.J.)

    2024  

    Abstract: Objective: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years, and hydroxychloroquine (HCQ) is the standard first-line treatment. Preeclampsia complicates up to one-third of pregnancies in lupus patients, ... ...

    Abstract Objective: Systemic lupus erythematosus (SLE) disproportionately affects women during childbearing years, and hydroxychloroquine (HCQ) is the standard first-line treatment. Preeclampsia complicates up to one-third of pregnancies in lupus patients, although reports vary by parity and multifetal gestation. We investigated whether taking HCQ early in pregnancy may reduce the risk of preeclampsia.
    Methods: We studied 1,068 live birth singleton pregnancies among 1,020 privately insured patients with SLE (2007-2016). HCQ treatment was defined as three months preconception through the first trimester, and prescription fills were a proxy for taking HCQ. Modified Poisson regression estimated risk ratios (RRs) and 95% confidence intervals (CIs), stratified by parity. Propensity scores accounted for confounders, and stratified analyses examined effect modification.
    Results: Approximately 15% of pregnant patients were diagnosed with preeclampsia. In 52% of pregnancies, patients had one or more HCQ fills. Pregnant patients exposed to HCQ had more comorbidities, SLE activity, and azathioprine treatment. We found no evidence of a statistical association between HCQ and preeclampsia among nulliparous (RR 1.26 [95% CI 0.82-1.93]) and multiparous pregnancies (RR 1.20 [95% CI 0.80-1.70]). Additional controls for confounding decreased the RRs toward the null (nulliparous pregnancy, propensity score-adjusted [PS-adj] RR 1.09 [95% CI 0.68-1.76]; multiparous pregnancy, PS-adj RR 1.01 [95% CI 0.66-1.53]).
    Conclusion: Using a large insurance-based database, we did not observe a decreased risk of preeclampsia associated with HCQ treatment in pregnancy, although we cannot rule out residual and unmeasured confounding and misclassification. Further studies leveraging large population-based data and prospective collection could characterize how HCQ influences preeclampsia risk in pregnant patients with SLE and among persons at greater risk of hypertensive disorders of pregnancy.
    Language English
    Publishing date 2024-01-25
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.42793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Antihypertensive Medication Use before and during Pregnancy and the Risk of Severe Maternal Morbidity in Individuals with Prepregnancy Hypertension.

    Bane, Shalmali / Wall-Wieler, Elizabeth / Druzin, Maurice L / Carmichael, Suzan L

    American journal of perinatology

    2022  Volume 41, Issue S 01, Page(s) e728–e738

    Abstract: Objective:  Our objective is to examine severe maternal morbidity (SMM) and patterns of antihypertensive medication use before and during pregnancy among individuals with chronic hypertension.: Study design:  We examined 11,759 pregnancies resulting ... ...

    Abstract Objective:  Our objective is to examine severe maternal morbidity (SMM) and patterns of antihypertensive medication use before and during pregnancy among individuals with chronic hypertension.
    Study design:  We examined 11,759 pregnancies resulting in a live birth or stillbirth to individuals with chronic hypertension and one or more antihypertensive prescription 6 months before pregnancy (Optum, 2007-17). We examined whether study outcomes were associated with the use of medication as compared to no use during pregnancy. In addition, patterns of medication use based on the Food and Drug Administration guidance and literature were evaluated. Medication use was divided into prepregnancy and during pregnancy use and classified as pregnancy recommended (PR) or not pregnancy recommended (nPR) or no medication use. SMM was defined per the Centers for Disease Control and Prevention definition of 21 indicators. Risk ratios (RR) reflecting the association of SMM with the use of antihypertensive medications were computed using modified Poisson regression with robust standard errors and adjusted for maternal age, education, and birth year.
    Results:  Overall, 83% of individuals filled an antihypertensive prescription during pregnancy and 6.3% experienced SMM. The majority of individuals with a prescription prior to pregnancy had a prescription for the same medication in pregnancy. Individuals with any versus no medication use in pregnancy had increased adjusted RR (aRR) of SMM (1.18, 95% confidence interval [CI]: 0.96-1.44). Compared to the use of PR medications before and during pregnancy, aRRs were 1.42 (95% CI: 1.18-1.69, 12.4% of sample) for nPR use before and during pregnancy, 1.52 (1.23-1.86; 12.4%) for nPR (before) and PR (during) use, and 2.67 (1.73-4.15) for PR and nPR use. Patterns with no medication use during pregnancy were not statistically significant.
    Conclusion:  Pattern of antihypertensive medication use before and during pregnancy may be associated with an elevated risk of SMM. Further research is required to elucidate whether this association is related to the severity of hypertension, medication effectiveness, or suboptimal quality of care.
    Key points: · Individuals with any medication use compared to no medication use in pregnancy had an increased risk of SMM.. · Specific medication use patterns were associated with an elevated risk of SMM.. · Pattern of antihypertensive medication use before and during pregnancy may be associated with an increased risk of SMM..
    MeSH term(s) Humans ; Pregnancy ; Female ; Antihypertensive Agents/therapeutic use ; Adult ; Hypertension/drug therapy ; Pregnancy Complications, Cardiovascular/drug therapy ; Young Adult ; United States
    Language English
    Publishing date 2022-10-19
    Publishing country United States
    Document type Journal Article
    ZDB-ID 605671-4
    ISSN 1098-8785 ; 0735-1631
    ISSN (online) 1098-8785
    ISSN 0735-1631
    DOI 10.1055/s-0042-1757354
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Severity of small-for-gestational-age and morbidity and mortality among very preterm neonates.

    Minor, Kathleen C / Bianco, Katherine / Sie, Lillian / Druzin, Maurice L / Lee, Henry C / Leonard, Stephanie A

    Journal of perinatology : official journal of the California Perinatal Association

    2022  Volume 43, Issue 4, Page(s) 437–444

    Abstract: Objective: Evaluate the association between small for gestational age (SGA) severity and morbidity and mortality in a contemporary, population of very preterm infants.: Study design: This secondary analysis of a California statewide database ... ...

    Abstract Objective: Evaluate the association between small for gestational age (SGA) severity and morbidity and mortality in a contemporary, population of very preterm infants.
    Study design: This secondary analysis of a California statewide database evaluated singleton infants born during 2008-2018 at 24-32 weeks' gestation, with a birthweight <15th percentile. We analyzed neonatal outcomes in relation to weight for gestational age (WGA) and symmetry of growth restriction.
    Results: An increase in WGA by one z-score was associated with decreased major morbidity or mortality risk (aRR 0.73, 95% CI 0.68-0.77) and other adverse outcomes. The association was maintained across gestational ages and did not differ by fetal growth restriction diagnosis. Symmetric growth restriction was not associated with neonatal outcomes after standardizing for gestational age at birth.
    Conclusions: Increasing SGA severity had a significant impact on neonatal outcomes among very preterm infants.
    MeSH term(s) Female ; Infant, Newborn ; Humans ; Fetal Growth Retardation ; Infant, Extremely Premature ; Infant, Small for Gestational Age ; Birth Weight ; Gestational Age ; Infant, Newborn, Diseases ; Infant, Premature, Diseases
    Language English
    Publishing date 2022-10-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645021-0
    ISSN 1476-5543 ; 0743-8346
    ISSN (online) 1476-5543
    ISSN 0743-8346
    DOI 10.1038/s41372-022-01544-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Antihypertensive Medication Use before and during Pregnancy and the Risk of Severe Maternal Morbidity in Individuals with Prepregnancy Hypertension

    Bane, Shalmali / Wall-Wieler, Elizabeth / Druzin, Maurice L. / Carmichael, Suzan L.

    American Journal of Perinatology

    2022  

    Abstract: Objective: Our objective is to examine severe maternal morbidity (SMM) and patterns of antihypertensive medication use before and during pregnancy among individuals with chronic hypertension.: Study Design: We examined 11,759 pregnancies resulting in ...

    Abstract Objective: Our objective is to examine severe maternal morbidity (SMM) and patterns of antihypertensive medication use before and during pregnancy among individuals with chronic hypertension.
    Study Design: We examined 11,759 pregnancies resulting in a live birth or stillbirth to individuals with chronic hypertension and one or more antihypertensive prescription 6 months before pregnancy (Optum, 2007–17). We examined whether study outcomes were associated with the use of medication as compared to no use during pregnancy. In addition, patterns of medication use based on the Food and Drug Administration guidance and literature were evaluated. Medication use was divided into prepregnancy and during pregnancy use and classified as pregnancy recommended (PR) or not pregnancy recommended (nPR) or no medication use. SMM was defined per the Centers for Disease Control and Prevention definition of 21 indicators. Risk ratios (RR) reflecting the association of SMM with the use of antihypertensive medications were computed using modified Poisson regression with robust standard errors and adjusted for maternal age, education, and birth year.
    Results: Overall, 83% of individuals filled an antihypertensive prescription during pregnancy and 6.3% experienced SMM. The majority of individuals with a prescription prior to pregnancy had a prescription for the same medication in pregnancy. Individuals with any versus no medication use in pregnancy had increased adjusted RR (aRR) of SMM (1.18, 95% confidence interval [CI]: 0.96–1.44). Compared to the use of PR medications before and during pregnancy, aRRs were 1.42 (95% CI: 1.18–1.69, 12.4% of sample) for nPR use before and during pregnancy, 1.52 (1.23–1.86; 12.4%) for nPR (before) and PR (during) use, and 2.67 (1.73–4.15) for PR and nPR use. Patterns with no medication use during pregnancy were not statistically significant.
    Conclusion: Pattern of antihypertensive medication use before and during pregnancy may be associated with an elevated risk of SMM. Further research is required to elucidate whether this association is related to the severity of hypertension, medication effectiveness, or suboptimal quality of care.
    Key Points: Individuals with any medication use compared to no medication use in pregnancy had an increased risk of SMM. Specific medication use patterns were associated with an elevated risk of SMM. Pattern of antihypertensive medication use before and during pregnancy may be associated with an increased risk of SMM.
    Keywords chronic hypertension ; pregnancy ; antihypertensive medication ; severe maternal morbidity ; preeclampsia ; eclampsia
    Language English
    Publishing date 2022-10-19
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 605671-4
    ISSN 1098-8785 ; 0735-1631
    ISSN (online) 1098-8785
    ISSN 0735-1631
    DOI 10.1055/s-0042-1757354
    Database Thieme publisher's database

    More links

    Kategorien

  10. Article: Intrahepatic Cholestasis of Pregnancy and Transaminitis in Women with COVID-19: A Case Series

    Waldrop, Anne R. / Henkel, Andrea / Lee, Kelley B. / Druzin, Maurice L. / Aziz, Natali / El-Sayed, Yasser / Lyell, Deirdre J.

    American Journal of Perinatology Reports

    2024  Volume 14, Issue 01, Page(s) e16–e18

    Abstract: Objective: The four initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant women presenting at term gestation to our institution presented with transaminitis. Three of the four were diagnosed with intrahepatic cholestasis ...

    Abstract Objective: The four initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected pregnant women presenting at term gestation to our institution presented with transaminitis. Three of the four were diagnosed with intrahepatic cholestasis of pregnancy (IHCP). Growing evidence exists of an associated transaminitis in nonpregnant SARS-CoV-2 patients. However, there are limited data of hepatic involvement of SARS-CoV-2 in pregnancy, and no previous studies have assessed the association with IHCP in patients with coronavirus disease 2019 (COVID-19).
    Study Design: This was a retrospective, single-center case series of four consecutive pregnant women with a positive result for SARS-CoV-2 presenting with transaminitis in third trimester.
    Results: The clinical courses of four pregnant women with COVID-19 and transaminitis, three of four of whom were diagnosed with IHCP, are described. Testing for SARS-CoV-2 was done through a reverse transcription polymerase chain reaction test of a nasopharyngeal swab.
    Conclusion: As we await larger studies ascertaining the incidence of IHCP in SARS-CoV-2, this prevalence highlights the importance of diagnosing IHCP among women with COVID-19 as a potential etiology of transaminitis, as IHCP risks may be ameliorated with earlier delivery. Moreover, delineating a hepatobiliary association in pregnancy may provide further information about the mechanism of liver impairment in SARS-CoV-2 in all patients.
    Keywords COVID-19 ; IHCP ; intrahepatic cholestasis of pregnancy ; maternal ; novel coronavirus ; SARS-CoV-2 ; transaminitis
    Language English
    Publishing date 2024-01-01
    Publisher Thieme Medical Publishers, Inc.
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2628074-7
    ISSN 2157-7005 ; 2157-6998
    ISSN (online) 2157-7005
    ISSN 2157-6998
    DOI 10.1055/s-0043-1777999
    Database Thieme publisher's database

    More links

    Kategorien

To top